Routes of Immunization and Flu Immune Responses (FLUWAY)

This study has been completed.
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01707602
First received: October 12, 2012
Last updated: August 2, 2013
Last verified: July 2013
  Purpose

The project aims to evaluate the impact of skin routes of immunization (transcutaneous and intradermal vs intramuscular) on cellular and humoral responses to seasonal influenza vaccination in adults (18-45 years old).


Condition Intervention Phase
Influenza
Biological: INTANZA® 15
Biological: Vaxigrip®
Biological: INTANZA® 15 T
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Impact of Immunization Routes on the Immune Response to Influenza Vaccine

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • CD8 T cell responses [ Time Frame: 21 days ] [ Designated as safety issue: No ]
    CD8 T cell responses against the specific vaccine strain will be measured at baseline and day 21 after vaccination by flow cytometry. Secretion of cytokines measured by intracellular staining will be compared between TC, ID and IM routes of vaccination.


Secondary Outcome Measures:
  • Safety [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
    Safety will be assessed at each visit by recording clinical local and systemic tolerance including reporting of adverse events. Frequency and severity of local and systemic adverse events following vaccination will be compared between TC, ID and IM vaccination groups.

  • Haemagglutination Inhibition [ Time Frame: 5 months ] [ Designated as safety issue: No ]
    Haemagglutination Inhibition and microneutralization assays will be performed at day0, day 21 and month 5 after vaccination to define the humoral response against a vaccine-homologous virus that meets or exceeds the EMEA (CHMP) guidance targets for influenza vaccine seroconversion rate (SCR), seroprotection rate (SPR), and geometric mean fold rise (GMFR).

  • CD4 T cell responses [ Time Frame: 21 days ] [ Designated as safety issue: No ]
    CD4 T cell responses against the specific vaccine strain will be measured at baseline and day 21 by intracellular staining and flow cytometry. Effector CD4 T cell responses will be compared between TC, ID and IM vaccination groups.

  • Memory CD8 and CD4 T cell responses [ Time Frame: 5 months ] [ Designated as safety issue: No ]
    Memory CD8 and CD4 T cell responses against the specific vaccine strain will be assessed by flow cytometry 5 month after vaccination by TC, ID and IM routes.

  • Inflammation [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Inflammation and systemic innate immune response will be assessed on day 1 after vaccination (compared with the basal inflammatory status) by studying the transcriptional profile of blood cells (microarrays) and inflammatory cytokines dosage in the serum.


Enrollment: 60
Study Start Date: October 2012
Study Completion Date: April 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
Biological: INTANZA® 15 T
transcutaneous vaccination
Active Comparator: Arm B
Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
Biological: INTANZA® 15
intradermal vaccination
Active Comparator: Arm C
Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
Biological: Vaxigrip®
Intramuscular vaccination

Detailed Description:

New approaches addressing intradermal (ID) and transcutaneous (TC) routes of immunization have been developed over the past few years and have brought novel insight in quality and efficacy of the immune response. Indeed, compared to the muscular tissue widely used for vaccination, the skin is particularly rich in antigen presenting cells. Our recent works show that penetration of vaccine compounds into the hair follicular ducts surrounded by Langerhans cells induces potent cellular immunity in contrast to the intra-muscular immunization. Our results also suggest that differential targeting of epidermal Langerhans cells (by TC route) or dermal dendritic cells (by ID route) could modulate the intensity and quality of the immune response to vaccine.

The aim of this study is to evaluate the immune response to a seasonal influenza vaccine when administrated byTC (hair follicular targeting needle-free method), ID (micro-needle injection) and IM (conventional intramuscular injection) routes of immunization. Along with our previous pre-clinical and clinical studies, here we hypothesize that differential targeting of epidermis or dermis antigen-presenting cells will have a differential impact on the cellular and humoral immune responses to Influenza vaccine.

Objectives:

We will conduct a phase I/II clinical trials on 60 healthy volunteers to compare TC and ID routes of immunization to the conventional intramuscular (IM) vaccination. The impact of these routes on cellular and humoral immune responses to seasonal influenza vaccine will be assessed at baseline, day 21 (effector phase) and month 5 (memory phase) after vaccination.

Outcomes:

Using the seasonal Influenza vaccine as an example of conventional vaccine, this study will evaluate and compare the efficacy ofTC, ID and IMroutes of immunization to induce cellular responses at day 21 and memory responses at month 5 phases. The generation and maintenance of Flu specific and neutralizing antibodies will be measured by Haemagglutination Inhibition and microneutralization assays.Moreover, safety and tolerance to each vaccination methods will be evaluated as well as inflammation and innate immune response induced at day 1 after vaccination.

Addressing innovative skin routes of immunization, this study represents an essential step to move forward in the development of new vaccination strategies. These results will have an important impact on the amelioration of vaccine efficacy and less invasive method of immunization.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers, age between 18 and 45 years,
  • BMI between 21 - 26,
  • Phototype I to IV,
  • Subjects able to receive vaccine administration by any of the three administration routes,
  • Signature of the written informed consent,
  • Affiliated to a health social security system,

Exclusion Criteria:

  • Known pregnancy or positive urine pregnancy test for women of child-bearing age,
  • Known infection with HIV or/and HCV or/and HBV (AgHBs+),
  • Known or suspected immune dysfunction that is caused by a medical condition, or any other Cause,
  • Use, within the past 3 months, of any topical and systemic treatment that would interfere with assessment and/or investigational treatment (anti-inflammatory drugs, immunosuppressors or any immune modulator agent),
  • Use of any topical treatment on the injection site within the last four weeks,
  • Excessive terminal hair growth on the two investigational skin areas used for the transcutaneous mode of vaccination,
  • Phototype V-VI,
  • Any allergy or hypersensibility to one of the components of the Investigational Product,
  • Medical history of allergy or hypersensitization to any ingredient of colorant used in the transcutaneous mode of administration,
  • Administration of a live vaccine(≤ 28 days) or inactivated (≤ 14 days) or planned vaccination within 3months of inclusion (D0),
  • Medical history of skin cancer,
  • Any acute skin affection which may interfere with the trial assessment on the injection site,
  • Any acute or chronic infectious which may interfere with the trial assessment four weeks prior to enrolment,
  • Prevision of UV sessions or sun exposure 6 weeks prior to the study or during the study period,
  • Febrile illness(at least 37.5°Cmeasuredorally), any acute infectious event within one week prior to enrolment,
  • Flu confirmed by the presence of fever≥38.5°Cassociated with respiratory symptoms
  • History of GuillainBarre syndrome or brachial neuritis following a previous vaccination.
  • Participation in an other biomedical research during the study period or period of exclusion when inclusion
  • Subject being in the exclusion period of a previous clinical trial,
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01707602

Locations
France
GH Cochin - Broca - Hôtel-Dieu CIC BT505
PARIS Cedex 14, France, 75679
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Principal Investigator: Odile LAUNAY, M.D. Ph. D AP-HP
  More Information

Publications:

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT01707602     History of Changes
Other Study ID Numbers: P120201, 2012-001967-55
Study First Received: October 12, 2012
Last Updated: August 2, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: French Data Protection Authority

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Intradermal
transcutaneous
influenza
routes of vaccination
T cell responses
humoral responses
skin
clinical trial
Novel application of influenza vaccine
Transcutaneous vaccination(hair follicular targeting)
Intradermal vaccination(micro-needle)

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 17, 2014